Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  TSX VENTURE EXCHANGE  >  Acasti Pharma Inc    ACST   CA00430K4028

ACASTI PHARMA INC

(ACST)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensus 
Quotes 5-day view   Delayed Quote. Delayed Tsx Venture Exchange
03/12/2019 03/13/2019 03/14/2019 03/15/2019 03/18/2019 Date
1.37(c) 1.42(c) 1.41(c) 1.43(c) 1.41(c) Last
26 807 124 300 13 062 15 806 29 590 Volume
-1.44% +3.65% -0.70% +1.42% -1.40% Change
More quotes
Financials (CAD)
Sales 2019 -
EBIT 2019 -32,3 M
Net income 2019 -46,3 M
Debt 2019 -
Yield 2019 -
Sales 2020 0,66 M
EBIT 2020 -22,1 M
Net income 2020 -27,1 M
Debt 2020 -
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
Capi. / Sales2019 0
Capi. / Sales2020 167x
Capitalization 110 M
More Financials
Company
Acasti Pharma Inc is a Canada-based biopharmaceutical company. The Company is focused on the research, development and commercialization of prescription drugs using omega 3 fatty acids (OM3s) derived from krill oil. OM3s has clinical evidence of safety and efficacy in lowering triglycerides in... 
Sector
Pharmaceuticals
Calendar
03/19 | 03:20pmPresentation
More about the company
Latest news on ACASTI PHARMA INC
03/13Acasti Pharma to Present at the Oppenheimer 29th Annual Healthcare Conference..
GL
02/14Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019
GL
02/08Acasti Pharma Schedules Third Quarter Fiscal 2019 Conference Call
GL
01/09Acasti Pharma Awarded Broad Composition-of-Matter and Method of Use Patents b..
GL
2018Acasti Pharma Announces TRILOGY Phase 3 Trials of CaPre® in Patients with Sev..
GL
2018Acasti Pharma Achieves Planned Enrollment Targets for TRILOGY Phase 3 Trials ..
GL
2018Acasti Pharma Schedules Second Quarter Fiscal 2019 Conference Call
GL
2018Acasti Pharma Announces Closing of $19.1 Million Underwritten Public Offering..
GL
2018ACASTI PHARMA : IIROC Trading Resumption - ACST
AQ
2018ACASTI PHARMA : IIROC Trading Halt - ACST
AQ
More news
Sector news : Pharmaceuticals - NEC
03/18EXCLUSIVE : Sanofi says working on CEO succession plan
RE
03/18SANOFI : Working on CEO Succession Plan -Reuters
DJ
03/18GLOBAL MARKETS LIVE : ING, Boeing, GM, Worldpay…
03/18ASTRAZENECA : Farxiga Trial Shows Reduction of Heart Problems in 16% of Patients
DJ
03/18ASTRAZENECA : Gets Orphan Drug Designation for Lung Disease Treatment
DJ
More sector news : Pharmaceuticals - NEC
Chart ACASTI PHARMA INC
Duration : Period :
Acasti Pharma Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 5,60  CAD
Spread / Average Target 297%
Managers
NameTitle
Janelle D'Alvise President, Chief Executive Officer & Director
Roderick N. Carter Executive Chairman
Pierre Lemieux Chief Operating & Scientific Officer
Jean-Francois Boily Vice President-Finance
Jean-Marie Canan Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ACASTI PHARMA INC23.68%83
JOHNSON & JOHNSON6.63%366 397
NOVARTIS11.61%238 367
ROCHE HOLDING LTD.11.61%233 055
PFIZER-4.28%231 954
MERCK AND COMPANY6.75%210 550